全文获取类型
收费全文 | 200547篇 |
免费 | 11941篇 |
国内免费 | 573篇 |
专业分类
耳鼻咽喉 | 1045篇 |
儿科学 | 5674篇 |
妇产科学 | 6939篇 |
基础医学 | 20438篇 |
口腔科学 | 5491篇 |
临床医学 | 21928篇 |
内科学 | 35205篇 |
皮肤病学 | 2287篇 |
神经病学 | 21525篇 |
特种医学 | 9787篇 |
外国民族医学 | 2篇 |
外科学 | 24378篇 |
综合类 | 1896篇 |
现状与发展 | 7篇 |
一般理论 | 36篇 |
预防医学 | 27144篇 |
眼科学 | 3377篇 |
药学 | 10984篇 |
11篇 | |
中国医学 | 642篇 |
肿瘤学 | 14265篇 |
出版年
2024年 | 231篇 |
2023年 | 11627篇 |
2022年 | 16406篇 |
2021年 | 16769篇 |
2020年 | 18045篇 |
2019年 | 11070篇 |
2018年 | 9852篇 |
2017年 | 11437篇 |
2016年 | 11003篇 |
2015年 | 9843篇 |
2014年 | 18100篇 |
2013年 | 12903篇 |
2012年 | 7642篇 |
2011年 | 5861篇 |
2010年 | 10323篇 |
2009年 | 9268篇 |
2008年 | 3559篇 |
2007年 | 3771篇 |
2006年 | 2780篇 |
2005年 | 2093篇 |
2004年 | 1462篇 |
2003年 | 1560篇 |
2002年 | 1681篇 |
2001年 | 1690篇 |
2000年 | 1241篇 |
1999年 | 1776篇 |
1998年 | 1733篇 |
1997年 | 1361篇 |
1996年 | 1530篇 |
1995年 | 1326篇 |
1994年 | 937篇 |
1993年 | 692篇 |
1992年 | 400篇 |
1991年 | 406篇 |
1990年 | 429篇 |
1989年 | 392篇 |
1988年 | 374篇 |
1987年 | 98篇 |
1986年 | 70篇 |
1985年 | 125篇 |
1984年 | 146篇 |
1983年 | 105篇 |
1982年 | 128篇 |
1981年 | 111篇 |
1980年 | 105篇 |
1979年 | 79篇 |
1978年 | 79篇 |
1977年 | 51篇 |
1976年 | 59篇 |
1974年 | 55篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
《Clinical genitourinary cancer》2022,20(1):1-10
IntroductionThe Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC).Methods and MaterialsPatients with mRCC and no prior systemic therapy were enrolled at academic and community sites. End of study data collection was in March 2019. Outcomes included overall survival (OS). A survey of treating physicians assessed reasons for treatment initiations and discontinuations.ResultsOverall, 376 patients with mRCC initiated first-line therapy; 171 (45.5%) received pazopanib, 75 (19.9%) sunitinib, and 74 (19.7%) participated in a clinical trial. Median (95% confidence interval) OS was longest in the clinical trial group (50.3 [35.8-not reached] months) versus pazopanib (39.0 [29.7-50.9] months) and sunitinib 26.2 [19.9-61.5] months). Non-clear cell RCC (21.5% of patients) was associated with worse median OS than clear cell RCC (18.0 vs. 47.3 months). Differences in baseline characteristics, treatment starting dose, and relative dose exposure among treatment groups suggest selection bias. Survey results revealed a de-emphasis on quality of life, toxicity, and patient preference compared with efficacy in treatment selection.ConclusionThe MaRCC Registry gives insights into real-world first-line treatment selection, outcomes, and physician rationale regarding initial treatment selection prior to the immunotherapy era. Differences in outcomes between clinical trial and off-study patients reflect the difficulty in translating trial results to real-world patients, and emphasize the need to broaden clinical trial eligibility. Physician emphasis on efficacy over quality of life and toxicity suggests more data and education are needed regarding these endpoints. 相似文献
73.
74.
75.
《Survey of ophthalmology》2023,68(4):815-820
An 8-year-old boy presented with acute visual loss in the right eye and nausea, vomiting, and diplopia. Imaging revealed a right orbital apex mass. Biopsy showed Langerhans cell histiocytosis (LCH), and the patient was diagnosed with isolated orbital LCH causing an orbital apex syndrome. A 12-month cytarabine chemotherapy course was begun, during which the patient developed bilateral optic disc edema. He was diagnosed with cytarabine-induced intracranial hypertension, which was successfully treated with acetazolamide. The cytarabine course was completed with complete resolution of the LCH lesion. The ophthalmologic relevance of this rare disorder is discussed. 相似文献
76.
BackgroundOptimal timing to initiate mechanical circulatory support (MCS) in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) remains unclear with studies showing conflicting results on whether to start before or after primary percutaneous coronary intervention (PPCI). This study aims to examine the association between mortality and MCS initiated before vs after PPCI in patients with STEMI complicated by CS.MethodsWe systematically searched PubMed, Embase, and Scopus for abstracts and full-text articles from inception to October 2021. Studies were included if they evaluated the association of mortality in patients who initiated MCS (specifically intra-aortic balloon pump (IABP), Impella, and venoarterial extracorporeal membrane oxygenation (VA-ECMO)) before PPCI versus after PPCI, specifically in patients with STEMI complicated by CS. Data were integrated using the random-effects models.ResultsTen studies involving 1,352 patients (956, 203, and 193 patients underwent IABP, Impella, and VA-ECMO respectively) with STEMI complicated by CS were included. There was no difference in mortality using IABP before or after PPCI ([OR] 1.77, 95% CI 0.77–1.61, I2 = 27%, p = 0.57). Nevertheless, Impella and VA-ECMO started before PPCI were significantly associated with a reduced risk of mortality compared to that started after PPCI ([OR] 0.49, 95% CI 0.26–0.92, I2 = 0%, p = 0.03 and [OR] 0.29, 95% CI 0.14–0.62, I2 = 0%, p = 0.001, respectively).ConclusionsIn patients with STEMI complicated by CS undergoing PPCI, the use of IMPELLA or VA-ECMO prior to PPCI significantly decreased mortality, in contrast to IABP, in which no difference in mortality was found between using it before or after PPCI. More rigorous studies are needed to clarify this association. 相似文献
77.
78.
79.
《HPB : the official journal of the International Hepato Pancreato Biliary Association》2022,24(9):1511-1518
BackgroundCholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced. Little data exists with respect to their incidence and treatment outcomes in low and middle income countries.MethodA retrospective analysis of a prospectively maintained database of all patients with perihilar (pCCA) and intrahepatic (iCCA) CCA registered between January 2012 and December 2018 was performed.ResultsA total of 760 patients, 427 (56.2%) diagnosed with pCCA and 333 (43.8%) of iCCA were included. Patients with localised, locally advanced and metastatic disease in pCCA were 45.5%, 25.9%, 8.5% and that in iCCA were 22.1%, 10.1% and 67.7% respectively. Only 141 (43.9%, 57 - iCCA, 84 -pCCA) of the total 321 patients started on some definitive cancer directed therapy could complete the intended treatment. The overall curative resection rate for all patients of iCCA was 14.5% whereas for patients of pCCA it was only 10.5%.ConclusionMore than half of CCA patients are not able to complete their intended treatment, being worse for pCCA as compared to iCCA. Early referral and centralisation of treatment for this complex disease might be the way forward to achieve optimal outcomes. 相似文献
80.